TY - JOUR
T1 - Depth and origin of prostatic involvement by urothelial carcinoma
T2 - Prognostic significance and staging interpretation
AU - Kiyoshima, Keijiro
AU - Kuroiwa, Kentaro
AU - Uchino, Hiroshi
AU - Yokomizo, Akira
AU - Naito, Seiji
PY - 2011/5
Y1 - 2011/5
N2 - Objective: To investigate the prognostic significance of prostatic involvement by bladder urothelial carcinoma using the new 2009 TNM staging system. Methods: From 1993 to 2008, 77 consecutive men who were clinically and/or pathologically diagnosed with bladder cancer underwent radical cystectomy. Patients were classified into several groups, according to the presence, extent and invading pathway of prostatic involvement by urothelial carcinoma, whether there was stromal or non-stromal involvement, and whether there was contiguous or non-contiguous involvement. Cause-specific survivals were calculated in each group and they were compared. Results: Prostatic involvement was observed in 23 (30%) patients: 10 had non-contiguous non-stromal involvement, 5 had non-contiguous stromal involvement and 8 had contiguous stromal involvement. Patients with stromal involvement (both contiguous and non-contiguous) showed significantly shorter cause-specific survival compared with those without prostatic stromal involvement (P = 0.002). The survival of patients with contiguous prostatic stromal involvement was similar to that of patients with non-contiguous prostatic stromal involvement (P = 0.79). Multivariate analysis showed that prostatic stromal involvement (both contiguous and non-contiguous) (hazard ratio, 8.4; P < 0.001), lymph node involvement (hazard ratio, 4.4; P = 0.016) and perivesical fat involvement (hazard ratio, 3.8; P = 0.029) were predictive of cause-specific survival. Conclusions: The depth of prostatic involvement has a significant impact on survival for patients with bladder urothelial carcinoma; however, whether its origin is contiguous or noncontiguous does not appear to be important.
AB - Objective: To investigate the prognostic significance of prostatic involvement by bladder urothelial carcinoma using the new 2009 TNM staging system. Methods: From 1993 to 2008, 77 consecutive men who were clinically and/or pathologically diagnosed with bladder cancer underwent radical cystectomy. Patients were classified into several groups, according to the presence, extent and invading pathway of prostatic involvement by urothelial carcinoma, whether there was stromal or non-stromal involvement, and whether there was contiguous or non-contiguous involvement. Cause-specific survivals were calculated in each group and they were compared. Results: Prostatic involvement was observed in 23 (30%) patients: 10 had non-contiguous non-stromal involvement, 5 had non-contiguous stromal involvement and 8 had contiguous stromal involvement. Patients with stromal involvement (both contiguous and non-contiguous) showed significantly shorter cause-specific survival compared with those without prostatic stromal involvement (P = 0.002). The survival of patients with contiguous prostatic stromal involvement was similar to that of patients with non-contiguous prostatic stromal involvement (P = 0.79). Multivariate analysis showed that prostatic stromal involvement (both contiguous and non-contiguous) (hazard ratio, 8.4; P < 0.001), lymph node involvement (hazard ratio, 4.4; P = 0.016) and perivesical fat involvement (hazard ratio, 3.8; P = 0.029) were predictive of cause-specific survival. Conclusions: The depth of prostatic involvement has a significant impact on survival for patients with bladder urothelial carcinoma; however, whether its origin is contiguous or noncontiguous does not appear to be important.
UR - http://www.scopus.com/inward/record.url?scp=79955820787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955820787&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyr013
DO - 10.1093/jjco/hyr013
M3 - Article
C2 - 21310731
AN - SCOPUS:79955820787
SN - 0368-2811
VL - 41
SP - 642
EP - 646
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 5
M1 - hyr013
ER -